While Roblox remains in the spotlight for these allegations, the company is also bringing lawsuits of its own. This year, the company has filed six trademark suits. Some of these lawsuits are against ...

Activist short-sellers are a controversial, but legal part of the financial world. Their strategy involves betting that a company stock price will decrease – shorting it – and publishing research that ...

Roblox’s Apple Store listing promises the “ultimate virtual universe that lets you create, share experiences with friends, and be anything you can imagine.” The video game platform plays host to ...

Geographically, the top venue for federal litigation involving Coca-Cola related companies is the Northern District of Georgia, where the company is based. Other areas include districts in population ...

Based on the regulatory filing that was just made public by the SEC, DTJ’s arrival had a transformative effect, with 1789’s assets under management closing in on a billion dollars – a more than ...

As biotech firm Sarepta Therapeutics (NASD: SRPT) battles patient deaths, regulatory action, and a cratering stock price, its dealings with the Food and Drug Administration are being monitored closely ...

As malls across America struggle for shoppers, DICK’S Sporting Goods, Inc. announced plans to acquire Foot Locker, Inc. for $2.5 billion. The merger agreement permits Foot Locker shareholders to elect ...

Short seller Christian Lamarco likes to court controversy. When he founded his New York firm in 2019, he named it Culper Research – after the Culper Spy Ring, which operated during the American ...

Bank consolidation has intensified, with a pair of bank mergers announced just a day apart: Columbia Banking System, Inc. announced plans to acquire Pacific Premier Bancorp, Inc. for $2 billion and ...

Alternative asset management firm TPG announced plans to acquire Sabre Corporation’s Hospitality Solutions business for $1.1 billion. The all-cash deal is projected to net Sabre $960 million, after ...

Novartis announced plans to acquire Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company developing medicines targeting microRNAs, for $800 million. The all cash deal includes a ...